Teva completed acquisition of Novopharm Limited in April 2000 for >$600M total consideration. Made Teva the largest generic drug company in North America with Novopharm's Canadian, US, and Hungarian operations.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 10yr post-close.
Key facts
AnnouncedApr 03, 2000
ClosedApr 03, 2000
Deal value$600M
Deal typeAcquisition/Merger
Therapeutic areaMultiple
IndicationsMultiple
Key assetsGeneric portfolio (Canadian and US generics)